IBIrene Bighelli

Irene Bighelli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Irene Bighelli has a total of 246 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment- and sham-related improvement and associated factors in non-invasive brain stimulation studies in treatment-resistant schizophrenia: a systematic review and meta-regression analysis

    by Yaohui Wei, Spyridon Siafis, Johannes Schneider‐Thoma, David D. Kim, Ulrike Vogelmann, Wolfgang Strube, Carolin Lorenz, Hui Wu, Nobuyuki Nomura, Shimeng Dong, et al.

  • Open Access

    Reconceptualizing Schizophrenia through a Patient-Oriented Perspective: a Systematic Review and Qualitative Meta-Synthesis

    by Sofia Francesca Aprile, Alessandro Rodolico, Djordje Basic, Kerem Böge, Markus Bühner, Christoph U Correll, Cristiano Cutuli, Peter Falkai, Gerhard Gründer, Alkomiet Hasan, et al.

    Background and Hypothesis: Schizophrenia spectrum disorders are typically described using positive and negative symptoms, yet standard diagnostic systems may not reflect the full range of how individuals experience the disorder. We hypothesized that synthesizing first-person accounts would yield a broader, clinically useful symptom framework that better represents lived experience. Study Design: We performed a systematic review and qualitative meta-synthesis following Enhancing Transparency in Reporting the Synthesis of Qualitative Research guidelines (PROSPERO: CRD420251069446). PubMed, PsycINFO, and Scopus were searched up to January 2026. Eligible studies used qualitative or mixed methods and reported first-person accounts from individuals with schizophrenia spectrum disorders. We included 52 peer-reviewed studies (2856 participants). We conducted two thematic syntheses: (1) general illness experience and (2) symptom experience organized using the Manual for Assessment and Documentation of Psychopathology in Psychiatry framework. Study Results: Across illness experience, five themes emerged: pervasive effects on physical, psychological, social, and relational life; stigma and isolation; interactions with medication, clinicians, and services; disruption and fragmentation of self, reality, and meaning; and coping strategies, including the protective role of social support. Across symptom experience, fear recurred across psychotic and non-psychotic domains, and participants often described psychosis as a transformed experience of reality rather than discrete symptoms. Accounts spanned disturbances in consciousness, perception, thinking, cognition, affect, and behavior. Conclusions: Lived experience highlights marked heterogeneity that extends beyond traditional symptom dichotomies and is only partly captured by current diagnostic frameworks. Incorporating patient-reported perspectives may support more nuanced, person-centered assessment and evaluation of treatment response.

  • Open Access

    Cognitive behavioral therapy for insomnia in people with schizophrenia: a systematic review and meta-analysis

    by Yuki Furukawa, Nurul Husna Salahuddin, Jingzhi Mao, Irene Bighelli, Stefan Leucht

  • Open Access

    Developing STEP‐SE: A Qualitative Usability Study of a Novel Patient‐Reported Outcomes Tool for Managing Side Effects in Shared Decision‐Making for Schizophrenia Spectrum Disorder Care

    by Alessandro Rodolico, Antonio Di Francesco, Pierfelice Cutrufelli, Irene Bighelli, Pasquale Caponnetto, Carmen Concerto, Davide Conti, Rosaria Furnari, Gabriele Leotta, Ludovico Mineo, et al.

    Background: Schizophrenia treatment with antipsychotics often results in side effects that impact adherence and quality of life. Managing these effects remains challenging, as it requires balancing efficacy and tolerability. The Schizophrenia Technological Evaluation of Patient Side Effects (STEP‐SE) app aims to aid side effects monitoring and management through shared decision‐making (SDM).Aim: This study aimed to evaluate the usability of the STEP‐SE app for patients and clinicians in managing antipsychotic side effects.Methods: Sixteen stable outpatients and 14 psychiatrists participated in semi‐structured interviews after using the STEP‐SE app. Questions explored ease of use, information clarity, user needs fulfilment, patient–clinician collaboration, treatment adherence improvement, patient empowerment and clinical utility. Data were analysed thematically.Results: Overall satisfaction with STEP‐SE was high. Both groups found that the tool improved patient involvement, provided reliable information to enhance therapeutic alliance, posed low risks of misunderstanding and had an intuitive interface. Patients felt more motivated and empowered. Clinicians appreciated guideline consistency. Preferences differed regarding data visualization formats.Discussion: STEP‐SE shows potential for aiding SDM on antipsychotic side effects. Patients gained motivation, and clinicians felt reassured. Refinements around mobile access, graphics and features could augment utility. Generalizability is limited given the stable patient sample.Conclusion: Preliminary findings suggest that STEP‐SE effectively engages patients, empowers them and supports clinicians in collaborative side effect management. Further testing with diverse user groups is warranted.Patient or Public Contribution: The current study was designed to gather patient and public feedback for the development of our decision aid tool, STEP‐SE. Participants interacted with the tool's prototype in interactive sessions, providing insights and identifying technical issues. Their feedback was crucial for enhancing the tool, with each suggestion and bug report carefully considered for future iterations. The participants’ contributions were key in optimizing STEP‐SE's features and ensuring its relevance and reliability. We thank all who shared their time and perspectives, significantly shaping the tool's user‐centred design.


  • Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis

    by Susanna Franziska Mayer, Ciaran Corcoran, Liam Kennedy, Stefan Leucht, Irene Bighelli

    Background Cognitive behavioural therapy (CBT) can be effective in the general population of people with schizophrenia. It is still unclear whether CBT can be effectively used in the population of people with a first‐episode or recent‐onset psychosis. Objectives To assess the effects of adding cognitive behavioural therapy to standard care for people with a first‐episode or recent‐onset psychosis. Search methods We conducted a systematic search on 6 March 2022 in the Cochrane Schizophrenia Group's Study‐Based Register of Trials, which is based on CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, PubMed, ClinicalTrials.gov, ISRCTN, and WHO ICTRP. Selection criteria We included randomised controlled trials (RCTs) comparing CBT added to standard care vs standard care in first‐episode or recent‐onset psychosis, in patients of any age. Data collection and analysis Two review authors (amongst SFM, CC, LK and IB) independently screened references for inclusion, extracted data from eligible studies and assessed the risk of bias using RoB2. Study authors were contacted for missing data and additional information. Our primary outcome was general mental state measured on a validated rating scale. Secondary outcomes included other specific measures of mental state, global state, relapse, admission to hospital, functioning, leaving the study early, cognition, quality of life, satisfaction with care, self‐injurious or aggressive behaviour, adverse events, and mortality. Main results We included 28 studies, of which 26 provided data on 2407 participants (average age 24 years). The mean sample size in the included studies was 92 participants (ranging from 19 to 444) and duration ranged between 26 and 52 weeks. When looking at the results at combined time points (mainly up to one year after start of the intervention), CBT added to standard care was associated with a greater reduction in overall symptoms of schizophrenia (standardised mean difference (SMD) ‐0.27, 95% confidence interval (CI) ‐0.47 to ‐0.08, 20 RCTs, n = 1508, I2 = 68%, substantial heterogeneity, low certainty of the evidence), and also with a greater reduction in positive (SMD ‐0.22, 95% CI ‐0.38 to ‐0.06, 22 RCTs, n = 1565, I² = 52%, moderate heterogeneity), negative (SMD ‐0.20, 95% CI ‐0.30 to ‐0.11, 22 RCTs, n = 1651, I² = 0%) and depressive symptoms (SMD ‐0.13, 95% CI ‐0.24 to ‐0.01, 18 RCTs, n = 1182, I² = 0%) than control. CBT added to standard care was also associated with a greater improvement in the global state (SMD ‐0.34, 95% CI ‐0.67 to ‐0.01, 4 RCTs, n = 329, I² = 47%, moderate heterogeneity) and in functioning (SMD ‐0.23, 95% CI ‐0.42 to ‐0.05, 18 RCTs, n = 1241, I² = 53%, moderate heterogeneity, moderate certainty of the evidence) than control. We did not find a difference between CBT added to standard care and control in terms of number of participants with relapse (relative risk (RR) 0.82, 95% CI 0.57 to 1.18, 7 RCTs, n = 693, I² = 48%, low certainty of the evidence), leaving the study early for any reason (RR 0.87, 95% CI 0.72 to 1.05, 25 RCTs, n = 2242, I² = 12%, moderate certainty of the evidence), adverse events (RR 1.29, 95% CI 0.85 to 1.97, 1 RCT, n = 43, very low certainty of the evidence) and the other investigated outcomes. Authors' conclusions This review synthesised the latest evidence on CBT added to standard care for people with a first‐episode or recent‐onset psychosis. The evidence identified by this review suggests that people with a first‐episode or recent‐onset psychosis may benefit from CBT additionally to standard care for multiple outcomes (overall, positive, negative and depressive symptoms of schizophrenia, global state and functioning). Future studies should better define this population, for which often heterogeneous definitions are used.


  • Cognitive behavioural therapy without medication for schizophrenia

    by Irene Bighellia, Oğulcan Çıraya, Nurul Husna Salahuddin, Stefan Leucht

    Background Cognitive behavioural therapy (CBT) can be effective in people with schizophrenia when provided in combination with antipsychotic medication. It remains unclear whether CBT could be safely and effectively offered in the absence of concomitant antipsychotic therapy. Objectives To investigate the effects of CBT for schizophrenia when administered without concomitant pharmacological treatment with antipsychotics. Search methods We conducted a systematic search on 6 March 2022 in the Cochrane Schizophrenia Group's Study‐Based Register of Trials, which is based on CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, PubMed, ClinicalTrials.gov, and WHO ICTRP. Selection criteria We included randomised controlled trials (RCTs) in people with schizophrenia comparing CBT without antipsychotics to standard care, standard care without antipsychotics, or the combination of CBT and antipsychotics. Data collection and analysis Two review authors independently screened references for inclusion, extracted data from eligible studies, and assessed risk of bias using Cochrane's RoB 2 tool. We contacted study authors for missing data and additional information. Our primary outcome was general mental state measured with a validated rating scale. Key secondary outcomes were specific symptoms of schizophrenia, relapse, service use, number of participants leaving the study early, functioning, quality of life, and number of participants actually receiving antipsychotics during the trial. We also assessed behaviour, adverse effects, and mortality. Main results We included 4 studies providing data for 300 participants (average age 21.94 years). The mean sample size was 75 participants (range 61 to 90 participants). Study duration was between 26 and 39 weeks for the intervention period and 26 to 104 weeks for the follow‐up period. Three studies employed a blind rater, while one study was triple‐blind. All analyses included data from a maximum of three studies. The certainty of the evidence was low or very low for all outcomes. For the primary outcome overall symptoms of schizophrenia, results showed a difference favouring CBT without antipsychotics when compared to no specific treatment at long term (> 1 year mean difference measured with the Positive and Negative Syndrome Scale (PANSS MD) −14.77, 95% confidence interval (CI) −27.75 to −1.79, 1 RCT, n = 34). There was no difference between CBT without antipsychotics compared with antipsychotics (up to 12 months PANSS MD 3.38, 95% CI −2.38 to 9.14, 2 RCTs, n = 63) (very low‐certainty evidence) or compared with CBT in combination with antipsychotics (up to 12 months standardised mean difference (SMD) 0.30, 95% CI −0.06 to 0.65, 3 RCTs, n = 125). Compared with no specific treatment, CBT without antipsychotics was associated with a reduction in overall symptoms (as described above) and negative symptoms (PANSS negative MD −4.06, 95% CI −7.50 to −0.62, 1 RCT, n = 34) at longer than 12 months. It was also associated with a lower duration of hospital stay (number of days in hospital MD −22.45, 95% CI −28.82 to −16.08, 1 RCT, n = 74) and better functioning (Personal and Social Performance Scale MD −12.42, 95% CI −22.75 to −2.09, 1 RCT, n = 40, low‐certainty evidence) at up to 12 months. We did not find a difference between CBT and antipsychotics in any of the investigated outcomes, with the exception of adverse events measured with the Antipsychotic Non‐Neurological Side‐Effects Rating Scale (ANNSERS) at both 6 and 12 months (MD −4.94, 95% CI −8.60 to −1.28, 2 RCTs, n = 48; MD −6.96, 95% CI −11.55 to −2.37, 2 RCTs, n = 42). CBT without antipsychotics was less effective than CBT combined with antipsychotics in reducing positive symptoms at up to 12 months (SMD 0.40, 95% CI 0.05 to 0.76, 3 RCTs, n = 126). CBT without antipsychotics was associated with a lower number of participants experiencing at least one adverse event in comparison with CBT combined with antipsychotics at up to 12 months (risk ratio 0.36, 95% CI 0.17 to 0.80, 1 RCT, n = 39, low‐certainty evidence). Authors' conclusions This review is the first attempt to systematically synthesise the evidence about CBT delivered without medication to people with schizophrenia. The limited number of studies and low to very low certainty of the evidence prevented any strong conclusions. An important limitation in the available studies was that participants in the CBT without medication group (about 35% on average) received antipsychotic treatment, highlighting the challenges of this approach. Further high‐quality RCTs are needed to provide additional data on the feasibility and efficacy of CBT without antipsychotics.


  • Open Access

    Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials

    by Spyridon Siafis, Johannes Schneider-Thoma, Tasnim Hamza, Irene Bighelli, Shimeng Dong, Wulf-Peter Hansen, John M Davis, Georgia Salanti, Stefan Leucht

    Introduction Guidelines recommend clozapine for treatment-resistant schizophrenia. However, meta-analysis of aggregate data (AD) did not demonstrate higher efficacy of clozapine compared with other second-generation antipsychotics but found substantial heterogeneity between trials and variation between participants in treatment effects. Therefore, we will conduct an individual participant data (IPD) meta-analysis to estimate the efficacy of clozapine compared with other second-generation antipsychotics while accounting for potentially important effect modifiers. Methods and analysis In a systematic review, two reviewers will independently search Cochrane Schizophrenia Group’s trial register (without restrictions in date, language or state of publication) and related reviews. We will include randomised controlled trials (RCTs) in participants with treatment-resistant schizophrenia comparing clozapine with other second-generation antipsychotics for at least 6 weeks. We will apply no restrictions in age, gender, origin, ethnicity or setting, but exclude open-label studies, studies from China, experimental studies and phase II of cross-over trials. IPD will be requested from trial authors and cross-check against published results. AD will be extracted in duplicate. Risk of bias will be assessed using Cochrane’s Risk of Bias 2 tool. The primary outcome will be overall symptoms of schizophrenia. We will synthesise results using random-effects meta-analysis and meta-regression methods in a 3-level Bayesian model. The model combines IPD with AD when IPD is not available for all studies, and include participant, intervention and study design characteristics as potential effect modifiers. The effect size measures will be mean difference (or standardised mean difference when different scales were used). Confidence in the evidence will be assessed using GRADE. Ethics and dissemination This project has been approved by the ethics commission of the Technical University of Munich (#612/21 S-NP). The results will be published open-access in a peer-review journal and a plain-language version of the results will be disseminated. If we need to amend this protocol, we will describe the change and give the rationale in a specific section in the resulting publication ‘Changes with respect to the protocol’. Systematic review registration PROSPERO (#CRD42021254986)


  • Open Access

    Effects of psychological treatments on functioning in people with Schizophrenia: a systematic review and meta-analysis of randomized controlled trials

    by Irene Bighelli, Sofia Wallis, Cornelia Reitmeir, Felicitas Schwermann, Nurul Husna Salahuddin, Stefan Leucht

    Functioning is recognized as a key treatment goal in alleviating the burden of schizophrenia. Psychological interventions can play an important role in improving functioning in this population, but the evidence on their efficacy is limited. We therefore aimed to evaluate the effect of psychological interventions in functioning for patients with schizophrenia. To conduct this systematic review and meta-analysis, we searched for published and unpublished randomized controlled trials (RCTs) in EMBASE, MEDLINE, PsycINFO, BIOSIS, Cochrane Library, WHO International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov and the Study register of the Cochrane Schizophrenia Group. The outcome functioning was measured with validated scales. We performed random-effects pairwise meta-analysis to calculate standardized mean differences (SMDs) with 95% confidence intervals (CIs). We included 58 RCTs (5048 participants). Psychological interventions analyzed together (SMD = – 0.37, 95% CI – 0.49 to – 0.25), cognitive behavioral therapy (30 RCTs, SMD = – 0.26, 95% CI – 0.39 to – 0.12), and third wave cognitive-behavioral therapies (15 RCTs, SMD = – 0.60, 95% CI – 0.83 to – 0.37) were superior to control in improving functioning, while creative therapies (8 RCTs, SMD = 0.01, 95% CI – 0.38 to 0.39), integrated therapies (4 RCTs, SMD = – 0.21, 95% CI – 1.20 to 0.78) and other therapies (4 RCTs, SMD = – 0.74, 95% CI – 1.52 to 0.04) did not show a benefit. Psychological interventions, in particular cognitive behavioral therapy and third wave cognitive behavioral therapies, have shown a therapeutic effect on functioning. The confidence in the estimate was evaluated as very low due to risk of bias, heterogeneity and possible publication bias.